Vanessa Carle - Apr 26, 2024 Form 4 Insider Report for Lexaria Bioscience Corp. (LEXX)

Role
Secretary
Signature
/Vanessa Carle/
Stock symbol
LEXX
Transactions as of
Apr 26, 2024
Transactions value $
$0
Form type
4
Date filed
5/10/2024, 05:24 PM
Previous filing
Nov 1, 2023
Next filing
May 15, 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding LEXX common shares 67 Apr 26, 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LEXX Stock Options Award $0 +10K +19.02% $0.00 62.6K Apr 26, 2024 Common Shares 10K $2.36 Direct
holding LEXX Warrants 67 Apr 26, 2024 Common Shares 67 $36.00 Direct
holding LEXX Stock Options 12.6K Apr 26, 2024 Common Shares 12.5K $3.00 Direct F1
holding LEXX Stock Options 17.6K Apr 26, 2024 Common Shares 5K $3.00 Direct F2
holding LEXX Stock Options 27.6K Apr 26, 2024 Common Shares 10K $3.00 Direct F3
holding LEXX Stock Options 40.1K Apr 26, 2024 Common Shares 12.5K $2.91 Direct
holding LEXX Stock Options 52.6K Apr 26, 2024 Common Shares 12.5K $1.15 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Repriced from $5.31 pursuant to shareholder approval received May 9, 2023
F2 Repriced from $7.08 pursuant to shareholder approval received May 9, 2023
F3 Repriced from $6.23 pursuant to shareholder approval received May 9, 2023